Celcuity (NASDAQ:CELC) Sets New 52-Week High – Here’s What Happened

Celcuity, Inc. (NASDAQ:CELC)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $129.09 and last traded at $125.68, with a volume of 995407 shares trading hands. The stock had previously closed at $121.03.

Analyst Ratings Changes

Several equities analysts have recently commented on CELC shares. Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Citizens Jmp initiated coverage on shares of Celcuity in a research note on Monday. They issued a “market outperform” rating and a $150.00 price target for the company. Citigroup initiated coverage on shares of Celcuity in a research note on Monday. They issued an “outperform” rating for the company. Finally, Stifel Nicolaus increased their price target on shares of Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $114.33.

Celcuity Trading Down 0.9%

The company has a market capitalization of $5.75 billion, a P/E ratio of -31.40 and a beta of 0.41. The stock’s 50 day moving average is $114.24 and its 200-day moving average is $101.73. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. As a group, equities research analysts anticipate that Celcuity, Inc. will post -3.97 earnings per share for the current year.

Insider Buying and Selling at Celcuity

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the completion of the transaction, the director owned 6,760 shares of the company’s stock, valued at approximately $745,425.20. This trade represents a 30.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.33% of the company’s stock.

Hedge Funds Weigh In On Celcuity

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Celcuity by 23.5% during the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock valued at $101,717,000 after purchasing an additional 391,262 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Celcuity by 68.0% during the third quarter. New York State Common Retirement Fund now owns 47,704 shares of the company’s stock valued at $2,357,000 after purchasing an additional 19,313 shares in the last quarter. Atle Fund Management AB bought a new position in shares of Celcuity during the third quarter valued at approximately $1,836,000. Candriam S.C.A. increased its stake in shares of Celcuity by 48.3% during the third quarter. Candriam S.C.A. now owns 390,924 shares of the company’s stock valued at $19,312,000 after purchasing an additional 127,348 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in shares of Celcuity by 2,142.0% during the third quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company’s stock valued at $772,000 after purchasing an additional 14,930 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.